Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Clinical trial NCT02625480 · COMPLETED

Trial details

NCT number: NCT02625480
Sponsor: Kite, A Gilead Company
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Start date: 2016-02-01
Primary completion: 2026-03-25
Enrollment: 95

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.